Depression in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

Volumn 12, Issue 2, 2011, Pages 109-112

  Atassi, Nazem ^a   Cook, Amanda ^a   Pineda, Cristiana M E ^a   Yerramilli Rao, Padmaja ^a   Pulley, Darlene ^a   Cudkowicz, Merit ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ALS; depression; enrollment; management; symptomatic

Indexed keywords

DOPAMINE UPTAKE INHIBITOR; RILUZOLE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS DEPRESSION INVENTORY; ANXIETY; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; DEPRESSION INVENTORY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSPNEA; FATIGUE; FEMALE; FUNCTIONAL STATUS; HUMAN; HYPERSALIVATION; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOBULBAR PALSY; SYMPTOM;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DEPRESSION; HUMANS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES;

EID: 79951759820     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482968.2010.536839     Document Type: Article

References (17)

1. Wicks P, Abrahams S, Masi D, Hejda-Forde S, Leigh PN, Goldstein LH. Prevalence of depression in a 12-month consecutive sample of patients with ALS. European Journal of Neurology. 2007;14:993-1001. (Pubitemid 47300772)
2. Hammer EM, Hä c ker S, Hautzinger M, Meyer TD, Kübler A. Validity of the ALS Depression Inventory (ADI-12): a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. Journal of Affective Disorders. 2008;109:213-9.
3. Rabkin JG, Albert SM, Del Bene ML, OSullivan I, Tider T, Rowland LP, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology. 2005;65:62-7. (Pubitemid 40967777)
4. Tedman BM, Young CA, Williams IR. Assessment of depression in patients with motor neuron disease and other neurologically disabling illness. J Neurol Sci. 1997;152:75-9.
5. Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology. 1999;52: 1434-40. (Pubitemid 29190537)
6. Kurt A, Nijboer F, Matuz T, Kubler A. Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs. 2007;21:279-91. (Pubitemid 46598449)
7. Chio A, Gauthier A, Montuschi A, Calvo A, Di Vito N, Ghiglione P, et al. A cross-sectional study on determinants of quality of life in ALS. J Neurol Neurosurg Psychiatry. 2004;75:1597-601. (Pubitemid 39430613)
8. Lou J-S, Reeves A, Benice T, Sexton G. Fatigue and depression are associated with poor quality of life in ALS. Neurology. 2003;60:122-3. (Pubitemid 36070659)
9. Kubler A, Winter S, Ludolph AC, Hautzinger M, Birbaumer N. Severity of depressive symptoms and quality of life in patients with amyotrophic lateral sclerosis. Neurorehabil Neural Repair. 2005;19:182-93. (Pubitemid 41216294)
10. McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA. Survival in amyotrophic lateral sclerosis: the role of psychological factors. Arch Neurol. 1994;51:17-23. (Pubitemid 24020167)
11. Bedlack RS, Pastula D, Welsh E, Pulley D, Cudkowicz ME. Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler. 2008;9:257-65.
12. Gorkin L, Schron EB, Handshaw K, Shea S, Kinney MR, Branyon M, et al. Clinical trial enrollers versus non-enrollers: The Cardiac Arrhythmia Suppression Trial (CAST) Recruitment and Enrollment Assessment in Clinical Trials (REACT) project. Controlled Clinical Trials. 1996;17:46-59. (Pubitemid 26120814)
13. Brooks BR. El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis". J Neurol Sci. 1994;124:96-107.
14. Spitzer RL, Williams JBW, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID) I: history, rationale, and description. Arch Gen Psychiatry. 1992;49: 624-9.
15. Riolo SA, Nguyen TA, Greden JF, King CA. Prevalence of depression by race/ethnicity: fi ndings from the National Health and Nutrition Examination Survey III. Am J Public Health. 2005;95:998-1000. (Pubitemid 40740711)
16. Hancock BW, Aitken M, Radstone C, Hudson GV. Why dont cancer patients get entered into clinical trials? Experience of the Sheffi eld Lymphoma Groups collaboration in British National Lymphoma Investigation studies. Br Med J. 1997;314:36-7. (Pubitemid 27023236)
17. Spiro SG, Gower NH, Evans MT, Facchini FM, Rudd RM. Recruitment of patients with lung cancer into a randomized clinical trial: experience at two centres. Thorax. 2000;55:463-5. (Pubitemid 30307262)